Diametric Capital’s CytomX Therapeutics CTMX Stock Holding History

Diametric Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-57,475	Closed	-$270K	–	520
2026 Q1	$270K	Buy	+57,475	New	+$292K	0.07%	353

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Diametric Capital's CTMX Position: Q2 2026 in Review

Diametric Capital sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 57,475 shares — an estimated $270K sold.

Diametric Capital first reported a position in CTMX in Q1 2026 and held it in 1 quarter. The position peaked at $270K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Diametric Capital reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
Diametric Capital sold 57,475 CytomX Therapeutics shares in Q2 2026, an estimated $270K.
Diametric Capital first reported a position in CytomX Therapeutics in Q1 2026 and held it in 1 quarter.
Diametric Capital's CytomX Therapeutics position peaked at $270K in Q1 2026.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.